← Back to screener

Dyne Therapeutics, Inc. DYN

Rank #2325 · Nasdaq · $2.4B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
24.4
P/E
-10.1
P/B
9.45
ROE
-93.5%
Op. Margin
–%
Debt Ratio
24%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -10.1x, P/B 9.45x. Ranks in the top 82% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -93.5%. Ranks in the top 94% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 24%. Ranks in the top 14% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020–$-0.0B$-0.0B$-0.0B–-49
2021–$-0.1B$-0.1B$0.0B–78
2022–$-0.2B$-0.1B$0.3B–17
2023–$-0.2B$-0.2B$0.4B–15
2024–$-0.2B$-0.2B$0.4B–20
2025–$-0.2B$-0.2B$0.3B–24

← See the full screener